# EDGAR Filing Document

**Accession Number:** 0000730272
**File Stem:** 0001193125-26-225380
**Filing Date:** 2026-5
**Character Count:** 6823
**Document Hash:** 1cea6281d773e6553361c0783dbc27ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-225380.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001193125-26-225380

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260514

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REPLIGEN CORP
- **CENTRAL INDEX KEY:** 0000730272
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 042729386
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-14656
- **FILM NUMBER:** 26982433

**BUSINESS ADDRESS:**
- **STREET 1:** 41 SEYON STREET
- **STREET 2:** BUILDING 1, SUITE 100
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 7814499560

**MAIL ADDRESS:**
- **STREET 1:** 41 SEYON STREET
- **STREET 2:** BUILDING 1, SUITE 100
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 14, 2026<br>

------

REPLIGEN CORP**ORATION**

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 000-14656 | 04-2729386 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 41 Seyon Street |  |  |
| Waltham**,** Massachusetts |  | 02453 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** **(781)** 250-0111<br>

**N/A**<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | RGEN | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.07 Submission of Matters to a Vote of Security Holders
On May 14, 2026, Repligen Corporation (the "Company") held its 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting"). As of March 16, 2026, the record date for the 2026 Annual Meeting, 56,399,274 shares of the Company's common stock were issued and outstanding, of which 54,022,359 shares were represented, in person or by proxy, at the 2026 Annual Meeting, constituting a quorum. At the 2026 Annual Meeting, the Company's stockholders voted on the following proposals, which are described in detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 2, 2026:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.to elect the nine (9) director nominees identified in the Proxy Statement to the Company's Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.to consider and ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.to consider and act upon a non-binding, advisory vote to approve the compensation of the Company's named executive officers.

Each of the director nominees in proposal 1 were duly elected by, and each of proposals 2 and 3 were approved by, the Company's stockholders at the 2026 Annual Meeting. The following voting results are final:

**Proposal 1 - Election of the Board of Directors**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Nominee** | **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| Olivier Loeillot | 51750665 | 116198 | 31383 | 2124113 |
| Martin Madaus, D.V.M., Ph.D. | 51091036 | 775295 | 31915 | 2124113 |
| Karen A. Dawes | 42726647 | 9132553 | 39046 | 2124113 |
| Nicolas M. Barthelemy | 51526602 | 339481 | 32163 | 2124113 |
| Carrie Eglinton Manner | 41987697 | 9871020 | 39529 | 2124113 |
| Konstantin Konstantinov, Ph.D. | 51137462 | 728874 | 31910 | 2124113 |
| Rohin Mhatre, Ph.D. | 51649920 | 215384 | 32942 | 2124113 |
| Glenn P. Muir | 38592456 | 13265484 | 40306 | 2124113 |
| Margaret A. Pax | 51011846 | 849103 | 37297 | 2124113 |

---

**Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 53,092,462 |  | 900,084 |  | 29,813 |  |  |

---

**Proposal 3 - Advisory Vote on Compensation of the Named Executive Officers**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **For** | **For** | **Against** | **Against** | **Abstain** | **Abstain** | **Broker Non-Votes** | **Broker Non-Votes** |
|  | 50,333,558 |  | 1,513,515 |  | 51,173 |  | 2,124,113 |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | REPLIGEN CORPORATION  | REPLIGEN CORPORATION  |
| Date: | May 15, 2026 | By:  | /s/ Olivier Loeillot |
|  |  |  | Olivier Loeillot  |
|  |  |  | President and Chief Executive Officer |

---

------